Treatment of Thrombotic Antiphospholipid Syndrome

The Rationale of Current Management - An Insight into Future Approaches

Cecilia Beatrice Chighizola, Tania Ubiali, Pier Luigi Meroni

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Vascular thrombosis and pregnancy morbidity represent the clinical manifestations of antiphospholipid syndrome (APS), which is serologically characterized by the persistent positivity of antiphospholipid antibodies (aPL). Antiplatelet and anticoagulant agents currently provide the mainstay of APS treatment. However, the debate is still open: controversies involve the intensity and the duration of anticoagulation and the treatment of stroke and refractory cases. Unfortunately, the literature cannot provide definite answers to these controversial issues as it is flawed by many limitations, mainly due to the recruitment of patients not fulfilling laboratory and clinical criteria for APS. The recommended therapeutic management of different aPL-related clinical manifestations is hereby presented, with a critical appraisal of the evidence supporting such approaches. Cutting edge therapeutic strategies are also discussed, presenting the pioneer reports about the efficacy of novel pharmacological agents in APS. Thanks to a better understanding of aPL pathogenic mechanisms, new therapeutic targets will soon be explored. Much work is still to be done to unravel the most controversial issues about APS management: future studies are warranted to define the optimal management according to aPL risk profile and to assess the impact of a strict control of cardiovascular risk factors on disease control.

Original languageEnglish
Article number951424
JournalJournal of Immunology Research
Volume2015
DOIs
Publication statusPublished - 2015

Fingerprint

Antiphospholipid Syndrome
Antiphospholipid Antibodies
Platelet Aggregation Inhibitors
Anticoagulants
Patient Selection
Blood Vessels
Thrombosis
Therapeutics
Stroke
Pharmacology
Morbidity
Pregnancy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Treatment of Thrombotic Antiphospholipid Syndrome : The Rationale of Current Management - An Insight into Future Approaches. / Chighizola, Cecilia Beatrice; Ubiali, Tania; Meroni, Pier Luigi.

In: Journal of Immunology Research, Vol. 2015, 951424, 2015.

Research output: Contribution to journalArticle

@article{a3e6d190fdfb4c5b813fe4b5073f3d0f,
title = "Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management - An Insight into Future Approaches",
abstract = "Vascular thrombosis and pregnancy morbidity represent the clinical manifestations of antiphospholipid syndrome (APS), which is serologically characterized by the persistent positivity of antiphospholipid antibodies (aPL). Antiplatelet and anticoagulant agents currently provide the mainstay of APS treatment. However, the debate is still open: controversies involve the intensity and the duration of anticoagulation and the treatment of stroke and refractory cases. Unfortunately, the literature cannot provide definite answers to these controversial issues as it is flawed by many limitations, mainly due to the recruitment of patients not fulfilling laboratory and clinical criteria for APS. The recommended therapeutic management of different aPL-related clinical manifestations is hereby presented, with a critical appraisal of the evidence supporting such approaches. Cutting edge therapeutic strategies are also discussed, presenting the pioneer reports about the efficacy of novel pharmacological agents in APS. Thanks to a better understanding of aPL pathogenic mechanisms, new therapeutic targets will soon be explored. Much work is still to be done to unravel the most controversial issues about APS management: future studies are warranted to define the optimal management according to aPL risk profile and to assess the impact of a strict control of cardiovascular risk factors on disease control.",
author = "Chighizola, {Cecilia Beatrice} and Tania Ubiali and Meroni, {Pier Luigi}",
year = "2015",
doi = "10.1155/2015/951424",
language = "English",
volume = "2015",
journal = "Journal of Immunology Research",
issn = "2314-8861",
publisher = "Hindawi Limited",

}

TY - JOUR

T1 - Treatment of Thrombotic Antiphospholipid Syndrome

T2 - The Rationale of Current Management - An Insight into Future Approaches

AU - Chighizola, Cecilia Beatrice

AU - Ubiali, Tania

AU - Meroni, Pier Luigi

PY - 2015

Y1 - 2015

N2 - Vascular thrombosis and pregnancy morbidity represent the clinical manifestations of antiphospholipid syndrome (APS), which is serologically characterized by the persistent positivity of antiphospholipid antibodies (aPL). Antiplatelet and anticoagulant agents currently provide the mainstay of APS treatment. However, the debate is still open: controversies involve the intensity and the duration of anticoagulation and the treatment of stroke and refractory cases. Unfortunately, the literature cannot provide definite answers to these controversial issues as it is flawed by many limitations, mainly due to the recruitment of patients not fulfilling laboratory and clinical criteria for APS. The recommended therapeutic management of different aPL-related clinical manifestations is hereby presented, with a critical appraisal of the evidence supporting such approaches. Cutting edge therapeutic strategies are also discussed, presenting the pioneer reports about the efficacy of novel pharmacological agents in APS. Thanks to a better understanding of aPL pathogenic mechanisms, new therapeutic targets will soon be explored. Much work is still to be done to unravel the most controversial issues about APS management: future studies are warranted to define the optimal management according to aPL risk profile and to assess the impact of a strict control of cardiovascular risk factors on disease control.

AB - Vascular thrombosis and pregnancy morbidity represent the clinical manifestations of antiphospholipid syndrome (APS), which is serologically characterized by the persistent positivity of antiphospholipid antibodies (aPL). Antiplatelet and anticoagulant agents currently provide the mainstay of APS treatment. However, the debate is still open: controversies involve the intensity and the duration of anticoagulation and the treatment of stroke and refractory cases. Unfortunately, the literature cannot provide definite answers to these controversial issues as it is flawed by many limitations, mainly due to the recruitment of patients not fulfilling laboratory and clinical criteria for APS. The recommended therapeutic management of different aPL-related clinical manifestations is hereby presented, with a critical appraisal of the evidence supporting such approaches. Cutting edge therapeutic strategies are also discussed, presenting the pioneer reports about the efficacy of novel pharmacological agents in APS. Thanks to a better understanding of aPL pathogenic mechanisms, new therapeutic targets will soon be explored. Much work is still to be done to unravel the most controversial issues about APS management: future studies are warranted to define the optimal management according to aPL risk profile and to assess the impact of a strict control of cardiovascular risk factors on disease control.

UR - http://www.scopus.com/inward/record.url?scp=84929650173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929650173&partnerID=8YFLogxK

U2 - 10.1155/2015/951424

DO - 10.1155/2015/951424

M3 - Article

VL - 2015

JO - Journal of Immunology Research

JF - Journal of Immunology Research

SN - 2314-8861

M1 - 951424

ER -